Goldman Sachs Comments on Amgen's (AMGN) Upcoming Kyprolis Ph-3 Blood Cancer Trials
Tweet Send to a Friend
Goldman Sachs maintained a Conviction Buy on Amgen (NASDAQ: AMGN) with a price target of $139. Analyst Terence Flynn commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
